NCT04263402 is a Phase 4 clinical trial of Methylprednisolone in 2019-nCoV Severe Pneumonia, sponsored by Tongji Hospital.

Who is sponsoring NCT04263402?

NCT04263402 is sponsored by Tongji Hospital.

What drugs are being tested in NCT04263402?

Interventions in NCT04263402: Methylprednisolone, Methylprednisolone.

What condition does NCT04263402 study?

NCT04263402 studies 2019-nCoV Severe Pneumonia.

Is NCT04263402 still recruiting?

NCT04263402 is currently status unknown. Last updated 17 March 2020.

Last reviewed 2020-03-17 · How we verify

NCT04263402

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia

Status unknown Phase 4 Last updated 17 March 2020

What this trial tests

Phase 4 trial testing Methylprednisolone in 2019-nCoV Severe Pneumonia in 100 participants. Status unknown.

Timeline

1 February 2020

Primary endpoint
1 June 2020

1 July 2020

Quick facts

Lead sponsor	Tongji Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	1 February 2020
Primary completion	1 June 2020
Estimated completion	1 July 2020
Sites	1 location across China

Drugs / interventions tested

Methylprednisolone (methylprednisolone) — full drug profile →
Methylprednisolone (methylprednisolone) — full drug profile →

Conditions studied

2019-nCoV Severe Pneumonia — all drugs for 2019-nCoV Severe Pneumonia →

Sponsor

Tongji Hospital

Who can join

18 and older, any sex, with 2019-nCoV Severe Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of different hormone doses in the treatment of 2019-nCoV severe Pneumonia.This study explores effective treatment programs for 2019-nCoV severe pneumonia and provides a reliable evidence-based basis for the treatment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B, Li M, Zhou Z, Guan X, et al · · 2020 · cited 507× · PMID 32291137 · DOI 10.1016/j.jaut.2020.102452
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044
A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
Tu YF, Chien CS, Yarmishyn AA, Lin YY, et al · · 2020 · cited 406× · PMID 32290293 · DOI 10.3390/ijms21072657
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
Lythgoe MP, Middleton P. · · 2020 · cited 247× · PMID 32291112 · DOI 10.1016/j.tips.2020.03.006
COVID-19: Characteristics and Therapeutics.
Chilamakuri R, Agarwal S. · · 2021 · cited 192× · PMID 33494237 · DOI 10.3390/cells10020206
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Controlling Cytokine Storm Is Vital in COVID-19.
Tang L, Yin Z, Hu Y, Mei H. · · 2020 · cited 123× · PMID 33329533 · DOI 10.3389/fimmu.2020.570993
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2020 · cited 105× · PMID 32717568 · DOI 10.1016/j.drup.2020.100719

Verify or expand the search:

Other trials of Methylprednisolone

Trials testing the same drug.

NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07455396 — Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Ped · Phase 2 · not yet recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07357935 — Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced · Phase 1, PHASE2 · not yet recruiting
NCT07265258 — A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease · Phase 4 · not yet recruiting

Other Tongji Hospital trials

Trials by the same sponsor.

NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04263402 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
Last refreshed: 17 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04263402.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing